CD34 and lymphoma: Moreover, the result of Figure 3(d) showed that pterostilbene treatments (20, 40, and 80 μM) have no toxicity in PBMCs and CD34+ cells from peripheral stem cells, further suggesting that pterostilbene is a safe agent for the treatment of T-cell leukemia/lymphoma.